Q24-27: Concomitant Therapy

Question 24: Did the recipient receive concomitant therapy?

Concomitant therapy is any therapy given to increase the effectiveness of the cellular therapy and can be given simultaneously with the infusion or any time post-infusion. In cases where a recipient has both HCT and cell therapy, this question applies to the cell therapy infusion, not the HCT. If the recipient had a prior HCT and the therapy was already captured on the HCT form as being the HCT preparative regimen, the drug should not be reported again.

!Concomitant Therapy
Do not report therapy given to prevent toxicities (e.g. CRS, neurotoxicity). Toxicity prophylaxis should be reported on the Pre-Cellular Therapy Baseline Data (4001) form if the infusion has been selected for CRF level reporting.

*Reporting More Than One Concomitant Therapy
Complete Specify start date and Specify drug by adding an additional instance in the FormsNet3^SM application.

Question 25: Specify start date

Report the start date of the drug being reported in this instance. Concomitant therapy can be given simultaneously with the cellular therapy infusion or given any time post-infusion.

For more information regarding reporting partial or unknown dates, see General Instructions, General Guidelines for Completing Forms.

Questions 26-27: Specify drugs

Select the drug given as concomitant therapy being reported in this instance. If the drug given is not in the list, check Other and specify the other drug.

Section Updates:

Question Number	Date of Change	Add/Remove/Modify	Description	Reasoning (If applicable)
.	.	.	.	.

Copyright © 2004-2025 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.